A Sos proteomimetic as a pan-Ras inhibitor

22Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

Abstract

Aberrant Ras signaling is linked to a wide spectrum of hyper-proliferative diseases, and components of the signaling pathway, including Ras, have been the subject of intense and ongoing drug discovery efforts. The cellular activity of Ras is modulated by its association with the guanine nucleotide exchange factor Son of sevenless (Sos), and the high-resolution crystal structure of the Ras-Sos complex provides a basis for the rational design of orthosteric Ras ligands. We constructed a synthetic Sos protein mimic that engages the wild-type and oncogenic forms of nucleotide-bound Ras and modulates downstream kinase signaling. The Sos mimic was designed to capture the conformation of the Sos helix-loop-helix motif that makes critical contacts with Ras in its switch region. Chemoproteomic studies illustrate that the proteomimetic engages Ras and other cellular GTPases. The synthetic proteomimetic resists proteolytic degradation and enters cells through macropinocytosis. As such, it is selectively toxic to cancer cells with up-regulated macropinocytosis, including those that feature oncogenic Ras mutations.

Author supplied keywords

Cite

CITATION STYLE

APA

Hong, S. H., Yoo, D. Y., Conway, L., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021). A Sos proteomimetic as a pan-Ras inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 118(18). https://doi.org/10.1073/pnas.2101027118

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free